ADVENTRX holds Type A gathering with FDA to discuss Exelbine NDA ADVENTRX Pharmaceuticals.

ADVENTRX holds Type A gathering with FDA to discuss Exelbine NDA ADVENTRX Pharmaceuticals, Inc. announced today that it held a Type A meeting with the U.S www.medicine-rx.com . Culley, CEO of ADVENTRX. ‘The Agency’s evaluation of the clinical data gives us self-confidence that a repeat study will be effective and that Exelbine can be approved.’ ‘Our money and equivalents of $40.7 million at July 31, plus cost savings from discontinuing the Exelbine program, will provide us the administrative centre to advance both our ANX-188 and ANX-514 applications into their respective pivotal clinical research next year. Culley added.D., Betsy and Clifton Robinson Seat in Biomedical Research, Southwestern Medical College, University of Texas.